RxTally.CA — Canadian maple leaf logoClarity in every comparison.
THE RxTally BLOG · 2026 ARCHIVE

What changed. Why it matters.

Canadian medication approvals, recalls, price developments and practical reading. In-depth explanations, practical context and links to the original evidence.

Articles are ordered by Last Update, newest first. Where no RxTally update is recorded, the original source date is used.

25 articles · Most recently updated first

Explainers

Generic semaglutide changed the coverage math. Here's the number to watch.

A McGill study in the Canadian Journal of Cardiology found generic semaglutide at $1,060 a year makes combination diabetes therapy cost-effective — and at $880 a year the case gets much stronger. What it means for coverage in Canada.

Explainers

Four Years of GLP-1 Thanksgiving Threads: What the Community Actually Discusses

RxTally analyzed 8 public Reddit threads from 2022–2025, representing roughly 390 visible comments, about mostly U.S. Thanksgiving discussions on Ozempic, Wegovy, Mounjaro and Zepbound — dosing debates, portions, side effects and the social politics of the small plate.

Explainers

Thanksgiving on a GLP-1: A Canadian Guide to Food, Doses and Family Questions

Taking Ozempic, Wegovy, Mounjaro or Zepbound this Thanksgiving? A Canadian guide to smaller portions, food tolerance, dose questions and what to say when family notices.

Industry & pricing

Ozempic savings card and private insurance: what to check before your next fill

Novo’s July announcement expanded eligibility outside Quebec. Your pharmacy still needs to confirm the current terms and your final bill.

Health Canada recalls

September Apo-Semaglutide recall: check the 4 mg pen and lot number

Health Canada’s September notice concerns DIN 02568012 and lot 7000636A. It is separate from the August recall.

Drug approvals

Sandoz generic Ozempic approved in Canada: what comes next?

Sandoz’s September approval adds another generic semaglutide option. Here is what the two DINs establish—and what remains unknown about stock and price.

Industry & pricing

Why a provider’s starting fee needs context

A free first visit can reduce an initial expense, but it does not describe the cost of continuing care.

Explainers

Zepbound without insurance: questions behind the published range

Without insurance, the most useful Zepbound cost is the complete cash amount for your exact fill.

Health Canada recalls

Apo-Semaglutide: a lot-specific dose-display recall

A recall headline should lead to a package check, not a conclusion about every medicine with the same ingredient.

Health Canada recalls

Dr. Reddy’s semaglutide: August impurity recall

An impurity recall requires attention to the affected product records and lots.

Industry & pricing

GLP-1 sales in Canada are on pace for a new record in 2026

About $2.4 billion in first-half retail sales puts Canada on a record-setting trajectory, according to IQVIA figures reported by The Globe and Mail.

Drug approvals

Mounjaro’s Canadian indication extends to ages 10–17 with type 2 diabetes

The age range in a drug-approval headline is only part of the authorization.

Industry & pricing

Ozempic savings card expands to eligible privately insured patients

A savings-card announcement describes program access, not a guaranteed payment for every prescription.

Drug approvals

Sevmia approval: the reference product matters

The Sevmia announcement is important because its reference product differs from earlier Canadian generic semaglutide approvals.

Drug approvals

Zepbound receives a Canadian sleep-apnea indication

A new indication can change the information a clinician considers without settling an individual treatment decision.

Explainers

Talking about semaglutide: decide what you want to share

You can decide how much of a treatment conversation to share with family or friends.

Explainers

Generic semaglutide in Canada: approvals, prices and practical questions

Generic semaglutide in Canada is a product-specific story: which medicine was authorized, what the pharmacy supplies, and what the final quote includes.

Industry & pricing

Novo Nordisk and Rexall announce a home-delivery partnership

Home delivery can change how a prescription reaches you without changing which costs remain payable.

Drug approvals

A second generic semaglutide approval adds an Apotex option

The second Canadian generic semaglutide approval added another manufacturer to follow.

Drug approvals

Canada’s first generic semaglutide approval: what changed

Canada’s first generic semaglutide approval was a regulatory milestone, not a universal pharmacy launch.

Explainers

Mounjaro prices: make the package and supply period visible

A useful Mounjaro comparison starts with the presentation, quantity and supply period—not the largest price printed on a page.

Explainers

Ozempic price ranges in Canada: how to read the headline

An Ozempic price range is only useful when the package and discount assumptions travel with it.

Drug approvals

Ozempic’s Canadian cardiovascular indication expands

News about an additional cardiovascular indication needs to be read with the population and product intact.

Safety advisories

Health Canada warns about fake and unauthorized GLP-1 products

A familiar ingredient name, convincing packaging or a low advertised price does not establish that an online product is authorized in Canada.

Drug approvals

Rybelsus receives a Canadian cardiovascular indication

Rybelsus is an oral semaglutide product, so its approval news should remain distinct from news about injectable semaglutide.

Selected 2026 news coverage; not a complete or real-time alert service. Consult the official notice for current safety information.